2022.02.17
NMPA Approval for Registration Applicati···
On February 11, 2022, Peijia Medical Limited (the “Company”) received the approval from the National···
2022.01.08
The First Clinical Case using HighLife T···
On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“···
2021.11.01
Peijia Medical Announces First Patient T···
A major breakthrough in interventional therapy for heart valve disease and an innovative progress in···
2021.09.14
Peijia Medical Announces First Patient I···
Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the···
2021.09.06
Peijia Medical Engages Professor Saibal ···
Peijia Medical Engages Professor Saibal Kar as Exclusive ConsultantTo Advise the Company’s Mitral Tr···
2021.08.09
TaurusOne® Valve clinical outcome publis···
TaurusOne® Valve clinical outcome published in EuroIntervention The first ever publication···
2021.06.26
With the second-generation transcatheter···
With the second-generation transcatheter aortic valve replacement system approved for marketing, Pei···
2021.06.25
Peijia Medical’s Jasper® SS Detachable C···
[June 24, SUZHOU] On June 15, 2021, Jasper® SS—a new detachable coil independently developed by···
2021.04.26
Peijia Medical’s TaurusOne® Transcathete···
A new interventional solution from China for structural heart disease is about to be launched onto t···
2021.02.01
Patient Enrollment Completed for Clinica···
On February 1, 2021, Peijia Medical announced that patient enrollment for clinical trial of Shenyi®&···
2020.12.04
Peijia Medical Successfully Commenced An···
Peijia Medical (HK Stock Code: 09996) successfully commenced the animal experiment for its mitral va···
